Literature DB >> 27109837

Right Ventricle before and after Atrial Septal Defect Device Closure.

Vidya Sagar Akula1, Rajasekhar Durgaprasad2, Vanajakshamma Velam1, Latheef Kasala1, Madhavi Rodda1, Harsha Vardhan Erathi1.   

Abstract

BACKGROUND: Percutaneous atrial septal defect (ASD) device closure is a safe and effective means of reducing or eliminating interatrial shunting. The response of the right heart to device closure is incompletely understood. AIM: To evaluate the effects of transcatheter closure of secundum ASD on right ventricle size and function, that is, both systolic and diastolic by transthoracic echocardiography (TTE) over a 6-month period.
METHODS: Seventy-three patients had 73 device implantations. The patients were assessed with echocardiography before and at 1 and 6 months after procedure.
RESULTS: Mean age was 26 ± 17 years. Mean ASD size indexed to body surface area (BSA) was 19.1 ± 8.6 mm/m(2) . The device size ranged from 12 to 42 mm. One month after closure, there were statistically significant decreases in right ventricular (RV) basal diameter (3.5 ± 0.7 cm vs. 4.2 ± 0.8 cm), RV/LV end-diastolic diameter ratio (0.9 ± 0.1 vs. 1.2 ± 0.2), left ventricular eccentricity index (LVEI) (1.0 ± 0.1 vs. 1.2 ± 0.2), right atrial (RA) major dimension (4.4 ± 0.8 cm vs. 4.8 ± 1.0 cm), RA end-systolic area (13.2 ± 4.6 cm(2) vs. 18.5 ± 6.7 cm(2) ), tricuspid annular plane systolic excursion (TAPSE) (2.2 ± 1.8 cm vs. 2.8 ± 0.5 cm), tricuspid annular systolic velocity (TASV or S') (13.1 ± 3.0 cm/sec vs. 16.0 ± 2.8 cm/sec), E/A (1.4 ± 0.3 vs. 1.7 ± 0.5), and E/e' (5.9 ± 5.0 vs. 7.2 ± 2.0) in comparison with baseline. Six months after closure, there were statistically significant decreases in RV major dimension (5.9 ± 1.1 cm vs. 6.3 ± 1.0 cm), RV/LV end-diastolic diameter ratio (0.8 ± 0.1 vs. 0.9 ± 0.1), RA major dimension (4.1 ± 0.8 cm vs. 4.4 ± 0.8 cm), and RA end-systolic area (11.4 ± 3.8 cm(2) vs. 13.2 ± 4.6 cm(2) ) in comparison with 1 month post-device closure. After 6 months, there was a statistically insignificant increase in both TASV (13.7 ± 2.8 cm/sec vs. 13.1 ± 3.0 cm/sec) and TAPSE (2.5 ± 1.6 cm/sec vs. 2.2 ± 1.8 cm/sec). There was no significant change in tissue Doppler MPI at baseline, 1 month, and 6 months after closure (0.38 ± 0.19 vs. 0.35 ± 0.15 vs. 0.38 ± 0.13). There was significant decrease in E/e' from baseline to 1 month and 1 month to 6 months after closure (7.2 ± 2.0 vs. 5.9 ± 5.0 vs. 4.7 ± 1.5).
CONCLUSION: RV volumes decreased significantly in the first month after ASD device closure and continued up to 6 months. There was no change in global right ventricular systolic function but a high basal RV systolic function decreased after closure. Some patients had impaired diastolic function before closure of defect, which reversed to normal within 6 months after closure. Diastolic dysfunction in older age-group may be a cause for long duration taken by right heart chambers to regress and deserves further investigation.
© 2016, Wiley Periodicals, Inc.

Entities:  

Keywords:  Tei index; atrial septal defect; diastolic function; left ventricle eccentricity index; tricuspid annular plane systolic excursion

Mesh:

Year:  2016        PMID: 27109837     DOI: 10.1111/echo.13250

Source DB:  PubMed          Journal:  Echocardiography        ISSN: 0742-2822            Impact factor:   1.724


  9 in total

1.  Assesment of Right Ventricle Function with Speckle Tracking Echocardiography after the Percutaneous Closure of Atrial Septal Defect.

Authors:  Onder Ozturk; Unal Ozturk; Mehmet Zilkif Karahan
Journal:  Acta Cardiol Sin       Date:  2017-09       Impact factor: 2.672

2.  Left and right ventricular speckle tracking study before and after percutaneous atrial septal defect closure in children.

Authors:  Hala M Agha; Islam S Mohammed; Hassan A Hassan; Hassan S Abu Seif; Ibrahim M Abu Farag
Journal:  J Saudi Heart Assoc       Date:  2020-04-17

3.  Right Ventricular Pump Efficiency in Secundum-Type Atrial Septal Defect.

Authors:  Wei-Tsung Lai; Ho-Ping Yu; Chang-Chyi Lin; Wei-Hsian Yin; Tsung-Yu Ko; Juey-Jen Hwang; Lung-Chun Lin; Kuan-Chih Huang
Journal:  Acta Cardiol Sin       Date:  2022-01       Impact factor: 2.672

Review 4.  Early Diagnosis of Cardiovascular Diseases in Workers: Role of Standard and Advanced Echocardiography.

Authors:  Lidia Capotosto; Francesco Massoni; Simone De Sio; Serafino Ricci; Antonio Vitarelli
Journal:  Biomed Res Int       Date:  2018-01-16       Impact factor: 3.411

5.  Normalization of the right heart and the preoperative factors that influence the emergence PAH after surgical closure of atrial septal defect.

Authors:  Supomo Supomo; Agung Widhinugroho; Aditya Agam Nugraha
Journal:  J Cardiothorac Surg       Date:  2020-05-20       Impact factor: 1.637

6.  Original Article--Predictors of Persistent Functional Tricuspid Regurgitation After Transcatheter Closure of Atrial Septal Defect and its Relationship to Tricuspid Valve Remodeling.

Authors:  Marwa Desoky Abohamar; Medhat Mohamed Ashmawy; Hanan Kamel Kasem; Ehab Abdelwahab Hamdy; Raghda Ghonimy El Sheikh
Journal:  J Saudi Heart Assoc       Date:  2021-04-15

7.  The Treatment Strategy for the Atrial Septal Defect in the Presence of Severe Pulmonary Hypertension.

Authors:  Evelina Zarambaitė; Grytė Ramantauskaitė; Aušra Krivickienė; Adakrius Siudikas; Skaidrius Miliauskas; Eglė Ereminienė
Journal:  Medicina (Kaunas)       Date:  2022-07-02       Impact factor: 2.948

8.  Impact of Right Ventricular Dilatation in Patients with Atrial Septal Defect.

Authors:  Rie Nakayama; Yoichi Takaya; Teiji Akagi; Koji Nakagawa; Nobuhisa Watanabe; Saori Nobusada; Toshi Matsushita; Norihisa Toh; Susumu Kanazawa; Hiroshi Ito
Journal:  J Interv Cardiol       Date:  2020-04-27       Impact factor: 2.279

9.  Biventricular reverse remodeling and relationship with mitral valve prolapse after transcatheter closure of ASD secundum, a 3D echocardiographic study.

Authors:  Amal El-Sisi; Shaheen Dabour; Aya M Fattouh; Effat Assar; Rasha Naguib; Antoine Fakhry AbdelMassih
Journal:  J Cardiovasc Thorac Res       Date:  2019-12-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.